

Form PTO-1449 (modified) Information Disclosure Statement by Applicant		ATTY. DOCKET NO. <b>0126-UTL</b>		SERIAL NO. <b>10/812,118</b>			
		APPLICANT <b>DREON et al.</b>					
		FILING DATE <b>7/2/2003</b>		GROUP			
Sheet 1 of 1							
U.S. Patent Documents							
Exam. Init.	Cite No.	Document Number	Name	Date MM-DD-YYYY	Addl. Ref.		
SUS	A1	8,381,806	Allen	03-28-2002			
Foreign Patent Documents							
Exam. Init.	Cite No.	Office	Document Number	Name	Date MM-DD-YYYY	Addl. Ref.	T
Other Documents (Including Author, Title, Date, Pertinent Pages, Etc.)							
Exam. Init.	Cite No.						T
Examiner Signature <i>[Signature]</i>				Date Considered <i>8/25/05</i>			



**Form PTO-1449 (modified)**  
**Information Disclosure Statement by**  
**Applicant**

Sheet 1 of 1

ATTY. DOCKET NO.  
**0125-UTL**

SERIAL NO.  
**10/612,118**

APPLICANT  
**DREON et al.**

FILING DATE  
**7/2/2003**

GROUP

**U.S. Patent Documents**

Exam. Init.	Cite No.	Document Number	Name	Date MM-DD-YYYY	Addl. Ref.
<i>SUS</i>	A1	4,758,592	Horrobin et al.	07-19-1988	
	A2	4,874,603	Fratzer	10-17-1989	
	A3	4,977,187	Horrobin	12-11-1990	
	A4	5,120,760	Horrobin	06-09-1992	
	A5	5,296,370q	Martin et al.	03-22-1994	
	A6	5,591,772	Lane et al.	01-07-1997	
	A7	5,750,516	Nakamura et al.	05-12-1998	
	A8	5,776,978	Bruzzese	07-07-1998	
	A9	6,054,128	Wakat	04-25-2000	
	A10	6,103,755	Bumann	08-15-2000	
	A11	6,187,811	Lane	02-13-2001	
	A12	6,346,544	Hensley et al.	02-12-2002	
	A13	6,361,806	Allen	03-26-2002	
	A14	6,391,309	Emple et al.	05-21-2002	
	A15	6,479,545	Levinson, et al.	11-12-2002	
	A16	6,617,349	Green et al.	09-09-2003	
	A17	6,645,514	Schneider et al.	11-11-2003	
	A18	2002/0015742	Jackson et al.	02-07-2002	
	A19	2002/0068100	Kapoor et al.	06-06-2002	
	A20	2002/0143049	Miller et al.	10-03-2002	
	A21	2002/0173510	Levinson et al.	11-21-2002	
	A22	2003/0013693	Guivarc'h et al.	01-16-2003	
	A23	2003/0050341	Bydlon et al.	03-13-2003	

**Foreign Patent Documents**

Exam. Init.	Cite No.	Office	Document Number	Name	Date MM-DD-YYYY	Addl. Ref.	T
<i>SUS</i>	B1		EP 0454102	Horrobin	10-31-1991		
	B2		EP 0573465	Martin	04-02-1997		
	B3		EP 0637957	Askanaazi et al.	07-23-1997		
	B4		EP 0699437	Bruzzese	03-06-1996		
	B5		EP 1260509	Brin et al.	11-27-2002		
	B6		EP 1275399	Killaan et al.	01-15-2003		
	B7		WO9929316	Mishra, et al.	06-17-1999		
	B8		WO02090977	Leeuwenburgh	11-14-2002		
	B9		WO03063793	Chilton et al.	08-07-2003		


**Other Documents**


Exam. Init.	Cite No.	(Including Author, Title, Date, Pertinent Pages, Etc.)	T
<i>SUS</i>	C1	ABRAHAM, G.E. "Nutritional factors in the etiology of the premenstrual tension syndromes." J. Reprod. Med., July 1983, Vol. 28, No. 7, pages 446-464.	
	C2	CONNELL, E.B. et al. "C-reactive protein in pregnancy and contraception". Am. J. Obstet. Gynecol. July 1971, Vol. 110, No. 5, pages 633-639.	
	C3	DRUGSTORE.COM "Natrol DHA Neuromins, 100mg softgels" October 30, 2002. www.drugstore.com	

*8/25/05*



Serial No. 10/612,118  
IDS Submitted 12/31/03

SVS	C4	DRUGSTORE.COM "Zone Perfect Omega 3 1000mg Capsules" October 30, 2002. <a href="http://www.drugstore.com">www.drugstore.com</a>	
	C5	FARMILA Dietary Supplements. "Fish Factor" November 8, 2002. <a href="http://www.farmila.it/otc/home_en.htm">http://www.farmila.it/otc/home_en.htm</a>	
	C6	JIANG, Q. et al. "Gamma-Tocopherol and its major metabolite, in contrast to alpha-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells". Proc. Natl. Acad. Sci. USA. October 10, 2000, Vol 97: No. 21, pages 11494-11499.	
	C7	LONDON, R.S. et al. "Efficacy of Alpha-tocopherol in the treatment of the premenstrual syndrome". J. Reprod. Med., June 1987, Vol. 32, No. 6, pages 400-404.	
	C8	LONDON, R.S. et al. "The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study." J. Am. Coll. Nutr. 1983, Vol. 2, pages 115-122.	
	C9	LONDON, R.S. et al. "The effect of alpha-tocopherol on premenstrual symptomatology: a double-blind study. II. Endocrine Correlates". J. Am. Coll. Nutr. 1984, Vol. 3, pages 351-356.	
	C10	RIDKER, P.M. et al. "C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women." N. Engl. J. Med., March 2003, Vol 342, No. 12, pages 836-843	
	C11	SEELIG, M.S. "Interrelationship of magnesium and estrogen in cardiovascular and bone disorders, eclampsia, migraine and premenstrual syndrome". J. Am. Coll. Nutr. 1993, Vol. 12, No. 4, pages 442-458.	
	C12	TIDOW-KEBRITCHI, S. et al. "Effects of Diets Containing Fish Oil and Vitamin E on Rheumatoid Arthritis" Nutrition Reviews, October 2001, Vol 59, No. 10, pages 335-341.	
	C13	TORASSA, U. "Protein may help predict risk of heart attacks" San Francisco Chronicle, November 14, 2002. page A16 Col. 1	
	C14	Van Langendonck, A. et al. "Oxidative stress and peritoneal endometriosis." Fertility & Sterility, May 2002, Vol. 77, No. 5, pages 861-870.	
	C15	Vandenbroucke, J.P. et al. "Oral contraceptives and the risk of venous thrombosis". N. Engl. J. Med., May 2001, Vol. 344, No. 20, pages 1527-1535.	
	C16	TORASSA, U. "Protein may help predict risk of heart attacks" San Francisco Chronicle, November 14, 2002. page A16 Col. 1	
Examiner Signature 		Date Considered 8/25/05	



Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete If Known

Application Number	10/612,118
Filing Date	07-02-2003
First Named Inventor	Dreon, D.
Group Art Unit	1614
Examiner Name	Unknown
Attorney Docket Number	0125-LIT

## U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
SUS	1	6,716,451		Udell et al.	04-06-2004	
	2	2004/0106674		Rich et al.	06-03-2004	
	3	2004/0082649		Rich et al.	04-29-2004	
	4	2004/0116512		Naguib et al.	06-17-2004	

## FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sub>6</sub>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>

Examiner Signature		Date Considered	8/25/05
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231